SCHEMBL1835937

SCHEMBL1835937

Cc1nn(-c2ccccc2)cc1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 2/20 0.51
ADORA1 P30542 6/20 0.50
ADORA2A P29274 5/20 0.50
ADORA2B P29275 3/20 0.50
HPGD P15428 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
MAPK1 P28482 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5021305 0.84 ADORA3 (0.45) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5020941 0.84 MAPT (0.40) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL25212519 0.82 MAOA (0.40) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL17619446 0.82 ALDH1A1 (0.54) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL9930636 0.81 NPC1 (0.46) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL9930836 0.81 NPC1 (0.46) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL2688474 0.80 CYP2A6 (0.45) MAPTSMN1; SMN2NPC1RAB9AHTT
SCHEMBL3568443 0.79 ADORA1 (0.51) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5341410 0.79 RAB9A (0.50) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL17619427 0.79 ALDH1A1 (0.51) MAPTSMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1189772-A Diaminopyrazole-containing compositions for colouring keratin fibres, colouring process, novel diaminopyrazoles and method for their prepn. OREAL (FR) 1998-08-05 CN claimed
WO-1996034591-A1 DIAMINOPYRAZOLE-CONTAINING COMPOSITIONS FOR COLOURING KERATIN FIBRES, COLOURING PROCESS, NOVEL DIAMINOPYRAZOLES AND METHOD FOR THEIR PREPARATION L'OREAL (FR) 1996-11-07 WO claimed
EP-0101664-B1 MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1986-06-04 EP claimed
EP-0101408-B1 MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1986-05-07 EP claimed
EP-0062607-B1 MONOAZO DYESTUFFS, THEIR PRAPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1986-04-23 EP claimed
EP-0101408-A1 Monoazo dyestuffs, their preparation and their use CIBA-GEIGY AG (CH) 1984-02-22 EP claimed
EP-0039306-B1 AZO DYESTUFFS, METHODS FOR THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1984-01-11 EP claimed
EP-0039306-A1 Azo dyestuffs, methods for their preparation and their use CIBA-GEIGY AG (CH) 1981-11-04 EP claimed
EP-3590933-B1 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS GENENTECH INC (US) 2021-01-06 EP disclosed
CN-108513574-B N-sulfonylated pyrazolo [3, 4-b ] pyridine-6-carboxamides and methods of use 艾伯维公司 2021-01-05 CN disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
EP-2638031-B9 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS GENENTECH INC (US) 2020-01-08 EP disclosed
EP-2638031-B9 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS GENENTECH INC (US) 2020-01-08 EP disclosed
EP-3124483-B1 PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS GENENTECH INC (US) 2019-07-10 EP disclosed
CN-1189772-A Diaminopyrazole-containing compositions for colouring keratin fibres, colouring process, novel diaminopyrazoles and method for their prepn. OREAL (FR) 1998-08-05 CN disclosed
WO-1996034591-A1 DIAMINOPYRAZOLE-CONTAINING COMPOSITIONS FOR COLOURING KERATIN FIBRES, COLOURING PROCESS, NOVEL DIAMINOPYRAZOLES AND METHOD FOR THEIR PREPARATION L'OREAL (FR) 1996-11-07 WO disclosed
EP-0039306-B1 AZO DYESTUFFS, METHODS FOR THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1984-01-11 EP disclosed
EP-0039306-A1 Azo dyestuffs, methods for their preparation and their use CIBA-GEIGY AG (CH) 1981-11-04 EP disclosed
US-4068085-A YELLOW AND RED ON POLYESTERS AND ACRYLICS CIBA-GEIGY CORPORATION (US) 1978-01-10 US disclosed
US-4033943-A Fiber reactive water soluble 2,4,6-triamino, 3-cyano pyridine-(5) azo dyestuffs CIBA-GEIGY CORPORATION (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885SMN1; SMN2 986/4885NPC1 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.